Literature DB >> 26842411

Bone-Grafting in Polyostotic Fibrous Dysplasia.

Arabella I Leet1, Alison M Boyce2, Khalda A Ibrahim3, Shlomo Wientroub4, Harvey Kushner5, Michael T Collins6.   

Abstract

BACKGROUND: Polyostotic fibrous dysplasia is a skeletal disease that results from somatic activating mutations in the gene GNAS in skeletal stem cells, leading to proliferation of immature osteogenic cells with replacement of normal marrow and bone with fibro-osseous tissue. Lesions may cause bone deformity or fracture. In the surgical care of polyostotic fibrous dysplasia, the role of grafting and the optimal grafting material are not clear. The purpose of this study was to evaluate the long-term survival of bone-grafting procedures in subjects with polyostotic fibrous dysplasia over time.
METHODS: The operative reports and radiographs of a cohort of subjects with polyostotic fibrous dysplasia followed in a natural history study were reviewed. Twenty-three subjects (mean age at the time of enrollment, thirteen years [range, two to forty years]) with fifty-two bone-grafting procedures had a mean follow-up time of 19.6 years (range, twenty-nine months to forty-seven years). Kaplan-Meier life table estimates, Cox proportional hazard models, and t tests comparing means were performed to assess various aspects of graft survival.
RESULTS: Kaplan-Meier curves showed a 50% estimate of survival of 14.5 years. Cox proportional hazards models showed no advantage comparing allograft with autograft or structural with nonstructural graft materials. The mean age of the patients was significantly greater (p < 0.001) in the subgroup of subjects in whom grafts were maintained over time (20.9 years) compared with the subgroup of patients whose grafts were resorbed over time (9.8 years).
CONCLUSIONS: Bone-grafting, including both allograft and autograft, is of limited value in ablating the lesions of fibrous dysplasia. The expectations of patients and surgeons should include the high probability of graft resorption over time with return of bone characteristics of fibrous dysplasia, particularly in younger patients. This suggests the maintenance of normal bone mechanics with implant support should be the priority of any surgical intervention.
Copyright © 2016 by The Journal of Bone and Joint Surgery, Incorporated.

Entities:  

Mesh:

Year:  2016        PMID: 26842411      PMCID: PMC4732545          DOI: 10.2106/JBJS.O.00547

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  28 in total

1.  Physical function is impaired but quality of life preserved in patients with fibrous dysplasia of bone.

Authors:  Marilyn H Kelly; Beth Brillante; Harvey Kushner; Pamela Gehron Robey; Michael T Collins
Journal:  Bone       Date:  2005-09       Impact factor: 4.398

2.  Identification of a mutation in the gene encoding the alpha subunit of the stimulatory G protein of adenylyl cyclase in McCune-Albright syndrome.

Authors:  W F Schwindinger; C A Francomano; M A Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

3.  Fibrous dysplasia of the proximal part of the femur. Long-term results of curettage and bone-grafting and mechanical realignment.

Authors:  J T Guille; S J Kumar; G D MacEwen
Journal:  J Bone Joint Surg Am       Date:  1998-05       Impact factor: 5.284

4.  An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone.

Authors:  Michael T Collins; Harvey Kushner; James C Reynolds; Caroline Chebli; Marilyn H Kelly; Anurag Gupta; Beth Brillante; Arabella I Leet; Mara Riminucci; Pamela Gehron Robey; Paolo Bianco; Shlomo Wientroub; Clara C Chen
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

5.  An activating Gs alpha mutation is present in fibrous dysplasia of bone in the McCune-Albright syndrome.

Authors:  A Shenker; L S Weinstein; D E Sweet; A M Spiegel
Journal:  J Clin Endocrinol Metab       Date:  1994-09       Impact factor: 5.958

Review 6.  Diseases of bone and the stromal cell lineage.

Authors:  P Bianco; P g Robey
Journal:  J Bone Miner Res       Date:  1999-03       Impact factor: 6.741

7.  Fibrous dysplasia of bone in the McCune-Albright syndrome: abnormalities in bone formation.

Authors:  M Riminucci; L W Fisher; A Shenker; A M Spiegel; P Bianco; P Gehron Robey
Journal:  Am J Pathol       Date:  1997-12       Impact factor: 4.307

8.  Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells.

Authors:  P Bianco; S A Kuznetsov; M Riminucci; L W Fisher; A M Spiegel; P G Robey
Journal:  J Clin Invest       Date:  1998-04-15       Impact factor: 14.808

9.  A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.

Authors:  Alison M Boyce; Marilyn H Kelly; Beth A Brillante; Harvey Kushner; Shlomo Wientroub; Mara Riminucci; Paolo Bianco; Pamela G Robey; Michael T Collins
Journal:  J Clin Endocrinol Metab       Date:  2014-07-17       Impact factor: 5.958

10.  Treatment of fibrous dysplasia involving the proximal femur.

Authors:  H N Shih; Y J Chen; T J Huang; K Y Hsu; R W Hsu
Journal:  Orthopedics       Date:  1998-12       Impact factor: 1.390

View more
  17 in total

1.  CORR Insights ® : What Is the Role of Allogeneic Cortical Strut Grafts in the Treatment of Fibrous Dysplasia of the Proximal Femur?

Authors:  Richard W Nicholas
Journal:  Clin Orthop Relat Res       Date:  2016-04-22       Impact factor: 4.176

Review 2.  Fibrous Dysplasia/McCune-Albright Syndrome: Clinical and Translational Perspectives.

Authors:  Cemre Robinson; Michael T Collins; Alison M Boyce
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 3.  Fibrous dysplasia of bone: craniofacial and dental implications.

Authors:  A B Burke; M T Collins; A M Boyce
Journal:  Oral Dis       Date:  2016-09-01       Impact factor: 3.511

Review 4.  Fibrous Dysplasia of Bone and McCune-Albright Syndrome: A Bench to Bedside Review.

Authors:  Iris Hartley; Maria Zhadina; Micheal T Collins; Alison M Boyce
Journal:  Calcif Tissue Int       Date:  2019-04-29       Impact factor: 4.333

5.  Fibrous dysplasia of bone: Surgical management options and outcomes of 22 cases.

Authors:  Xiang Fang; Hongyuan Liu; Yun Lang; Yan Xiong; Hong Duan
Journal:  Mol Clin Oncol       Date:  2018-05-21

Review 6.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 7.  The Clinical Spectrum of McCune-Albright Syndrome and Its Management.

Authors:  Tiahna Spencer; Kristen S Pan; Michael T Collins; Alison M Boyce
Journal:  Horm Res Paediatr       Date:  2019-12-19       Impact factor: 2.852

8.  18 F-NaF PET/CT IMAGING IN FIBROUS DYSPLASIA OF BONE.

Authors:  Georgios Z Papadakis; Georgios C Manikis; Apostolos H Karantanas; Pablo Florenzano; Ulas Bagci; Kostas Marias; Michael T Collins; Alison M Boyce
Journal:  J Bone Miner Res       Date:  2019-05-22       Impact factor: 6.390

9.  Individualized approach to the surgical management of fibrous dysplasia of the proximal femur.

Authors:  Bas C J Majoor; Andreas Leithner; Michiel A J van de Sande; Natasha M Appelman-Dijkstra; Neveen A T Hamdy; P D Sander Dijkstra
Journal:  Orphanet J Rare Dis       Date:  2018-05-02       Impact factor: 4.123

Review 10.  Fibrous Dysplasia/McCune-Albright Syndrome: A Rare, Mosaic Disease of Gα s Activation.

Authors:  Alison M Boyce; Michael T Collins
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.